Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Short-term Investments (2016 - 2021)

Historic Short-term Investments for Aytu Biopharma (AYTU) over the last 6 years, with Q3 2021 value amounting to $252000.0.

  • Aytu Biopharma's Short-term Investments changed 0.0% to $252000.0 in Q3 2021 from the same period last year, while for Sep 2021 it was $252000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $252000.0 for FY2021, which is 39.84% up from last year.
  • Aytu Biopharma's Short-term Investments amounted to $252000.0 in Q3 2021, which was down 0.0% from $252000.0 recorded in Q2 2021.
  • Aytu Biopharma's 5-year Short-term Investments high stood at $252000.0 for Q3 2020, and its period low was $75214.0 during Q2 2017.
  • Over the past 5 years, Aytu Biopharma's median Short-term Investments value was $250500.0 (recorded in 2019), while the average stood at $195591.4.
  • As far as peak fluctuations go, Aytu Biopharma's Short-term Investments crashed by 9277.73% in 2017, and later soared by 15083.16% in 2019.
  • Quarter analysis of 5 years shows Aytu Biopharma's Short-term Investments stood at $75214.0 in 2017, then surged by 33.25% to $100225.0 in 2018, then skyrocketed by 150.83% to $251396.0 in 2019, then grew by 0.24% to $252000.0 in 2020, then changed by 0.0% to $252000.0 in 2021.
  • Its Short-term Investments stands at $252000.0 for Q3 2021, versus $252000.0 for Q2 2021 and $252000.0 for Q1 2021.